A better DNA material for genetic medicine
With its circular single-stranded DNA molecules, MIT spinout Kano Therapeutics plans to make gene and cell therapies safer and more effective.
With its circular single-stranded DNA molecules, MIT spinout Kano Therapeutics plans to make gene and cell therapies safer and more effective.
Using a versatile problem-solving framework, researchers show how early relapse in lymphoma patients influences their chance for survival.
Preliminary studies find derivatives of the compound, known as verticillin A, can kill some types of glioma cells.
BoltzGen generates protein binders for any biological target from scratch, expanding AI’s reach from understanding biology toward engineering it.
Using these antigens, researchers plan to develop vaccine candidates that they hope would stimulate a strong immune response against the world’s deadliest pathogen.
Selective crystallization can greatly improve the purity, selectivity, and active yield of viral vector-based gene therapy drugs, MIT study finds.
Adding amino acids to certain protein-based medications can improve stability and effectiveness. New MIT research demonstrates how it works.
MIT CSAIL and McMaster researchers used a generative AI model to reveal how a narrow-spectrum antibiotic attacks disease-causing bacteria, speeding up a process that normally takes years.
The gathering of Biogen and MIT employees, business leaders, and public officials celebrated the first building to be constructed at Kendall Common.
VaxSeer uses machine learning to predict virus evolution and antigenicity, aiming to make vaccine selection more accurate and less reliant on guesswork.
Solubility predictions could make it easier to design and synthesize new drugs, while minimizing the use of more hazardous solvents.
The team used two different AI approaches to design novel antibiotics, including one that showed promise against MRSA.
The platform identifies, mixes, and tests up to 700 new polymer blends a day for applications like protein stabilization, battery electrolytes, or drug-delivery materials.
The Fairbairn Menstruation Science Fund will allow researchers to accelerate the understanding and treatment of often-neglected diseases that tend to be more common in women.
By delivering an HIV vaccine candidate along with two adjuvants, researchers showed they could generate many more HIV-targeting B cells in mice.